We have recently reported an alternative cell therapy approach to induce angiogenesis. The approach is based on small organ fragments – micro-organs (MOs) – whose geometry allows preservation of the natural epithelial/mesenchymal interactions and ensures appropriate diffusion of nutrients and gases to all cells. We have shown that lung-derived MOs, when implanted into hosts, transcribe a wide spectrum array of angiogenic factors and can induce an angiogenic response that can rescue experimentally induced ischemic regions in mice.From a clinical perspective, skin-derived MOs are particularly appealing as they could readily be obtained from a skin biopsy taken from the same target patient. In the present work we have investigated the angiogenesis-inducing capacity of rabbit and human skin-derived micro-organs in vitro and in vivo. Rabbit skin MOs were implanted into homologous adult rabbits and human skin MOs were encapsulated and implanted into xenogenic mice. Skin-derived MOs, as lung-derived MOs, were found to secrete a whole array of angiogenic factors and to induce a powerful angiogenic response when implanted back into animals. We believe the approach presented suggests a novel, efficacious and simple approach for therapeutic angiogenesis.

Keywords:
Angiogenesis, Vessel formation, Cell therapy, Multifactorial approach, Encapsulation
1.
Syed IS, Sanborn TA, Rosengart TK: Therapeutic angiogenesis: a biologic bypass. Cardiology 2004;101:131–143.
2.
Weitz JI, Byrne J, Clagett GP, Farkouh ME, Porter JM, Sackett DL, Strandness DE Jr, Taylor LM: Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026–3049.
3.
Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA: Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol 2001;41:378–385.
4.
Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL, Gold JP, Simons M: Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100:1865–1871.
5.
Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102:1605–1610.
6.
Idris NM, Haider H, Goh MW, Sim EK: Therapeutic angiogenesis for treatment of peripheral vascular disease. Growth Factors 2004;22:269–279.
7.
Isner JM, Asahara T: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231–1236.
8.
Carmeliet P: VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med 2000;6:1102–1103.
9.
Ferrara N, Alitalo K: Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359–1364.
10.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–248.
11.
Asahara T: Takayuki Asahara, MD, PHD Interview by Vicki P. Glaser. J Hematother Stem Cell Res 2002;11:579–582.
12.
Asahara T, Isner JM: Endothelial progenitor cells for vascular regeneration. J Hematother Stem Cell Res 2002;11:171–178.
13.
Masuda H, Kalka C, Asahara T: Endothelial progenitor cells for regeneration. Hum Cell 2000;13:153–160.
14.
Murayama T, Asahara T: Bone marrow-derived endothelial progenitor cells for vascular regeneration. Curr Opin Mol Ther 2002;4:395–402.
15.
Asahara T, Kawamoto A: Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol 2004;287:C572–C579.
16.
Hasson E, Arbel D, Verstandig A, Shimoni Y, Mitrani E: A cell-based multifactorial approach to angiogenesis. J Vasc Res 2005;42:29–37.
17.
Hasson E, Slovatizky Y, Shimoni Y, Falk H, Panet A, Mitrani E: Solid tissues can be manipulated ex vivo and used as vehicles for gene therapy. J Gene Med 2005;7:926–935.
18.
Mitrani E, Nadel G, Hasson E, Harari E, Shimoni Y: Epithelial-mesenchymal interactions allow for epidermal cells to display an in vivo-like phenotype in vitro. Differentiation 2005; 73:79–87.
19.
Kennedy DW, Abkowitz JL: Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 1997;90:986–993.
20.
Chomczynski P: Single-step method of total RNA isolation by acid guanidine-phenol extraction; in Celis JE (ed): Cell Biology: A Laboratory Handbook. New York, Academic Press, 1994, vol 1, pp 680–683.
21.
Deveci D, Egginton S: Development of the fluorescent microsphere technique for quantifying regional blood flow in small mammals. Exp Physiol 1999;84:615–630.
22.
Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defined by pericyte10/18/2005 coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591–1598.
23.
Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER: Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872–880.
24.
Richardson TP, Peters MC, Ennett AB, Mooney DJ: Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19:1029–1034.
25.
Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N: Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 1987;329:630–632.
26.
Schwenter F, Schneider BL, Pralong WF, Deglon N, Aebischer P: Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther 2004;15:669–680.
27.
Gershonowitz A, Itach EG, Shouval D, Mitrani D, Ilan Y, Mitrani E: Development of a scaled up liver device incorporating cryo-preserved pig liver micro-organs. J Hepatol 2004;41:950–956.
28.
Sommer B, Rinsch C, Payen E, Dalle B, Schneider B, Deglon N, Henri A, Beuzard Y, Aebischer P: Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol Ther 2002;6:155–161.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.